Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.77 -2.5%	$2.42	$1.78 ▼ $8.58	$57.87M	0.7	247,559 shs	120,119 shs
CUE Cue Biopharma	$0.90 +7.1%	$0.70	$0.45 ▼ $1.99	$67.81M	1.43	426,245 shs	494,045 shs
HOWL Werewolf Therapeutics	$1.41 +0.7%	$1.19	$0.60 ▼ $4.18	$63.27M	0.62	443,651 shs	402,513 shs
LEXX Lexaria Bioscience	$0.95 +8.7%	$0.96	$0.79 ▼ $4.38	$18.49M	0.79	147,787 shs	392,266 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	+9.06%	+20.96%	-5.46%	-68.45%
CUE Cue Biopharma	0.00%	+17.49%	+37.30%	+18.11%	+0.28%
HOWL Werewolf Therapeutics	0.00%	+18.49%	+13.71%	+53.43%	-51.04%
LEXX Lexaria Bioscience	0.00%	+7.33%	-5.45%	-31.49%	-67.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.1695 of 5 stars	3.4	4.0	4.8	0.0	2.5	0.6
CUE Cue Biopharma	3.5597 of 5 stars	3.5	2.0	4.7	0.0	0.8	0.6
HOWL Werewolf Therapeutics	3.497 of 5 stars	3.5	5.0	0.0	0.0	5.0	0.6
LEXX Lexaria Bioscience	1.8047 of 5 stars	3.5	2.0	0.0	0.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	759.21% Upside
CUE Cue Biopharma	3.00	Buy	$3.00	233.33% Upside
HOWL Werewolf Therapeutics	3.00	Buy	$8.33	491.02% Upside
LEXX Lexaria Bioscience	3.00	Buy	$5.00	428.82% Upside

Current Analyst Ratings Breakdown

Latest LEXX, CUE, HOWL, and ADVM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	LEXX Lexaria Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/9/2025	HOWL Werewolf Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $6.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	57.87	N/A	N/A	$3.40 per share	0.81
CUE Cue Biopharma	$9.29M	7.30	N/A	N/A	$0.28 per share	3.21
HOWL Werewolf Therapeutics	$1.14M	55.36	N/A	N/A	$1.65 per share	0.85
LEXX Lexaria Bioscience	$615.92K	30.02	N/A	N/A	$0.26 per share	3.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
CUE Cue Biopharma	-$40.67M	-$0.67	N/A	N/A	N/A	-507.87%	-228.43%	-114.66%	8/13/2025 (Estimated)
HOWL Werewolf Therapeutics	-$70.51M	-$1.67	N/A	N/A	N/A	N/A	-89.37%	-54.87%	8/14/2025 (Estimated)
LEXX Lexaria Bioscience	-$5.80M	-$0.67	N/A	N/A	N/A	-1,849.19%	-157.22%	-133.69%	N/A

Latest LEXX, CUE, HOWL, and ADVM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HOWL Werewolf Therapeutics	-$0.50	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	CUE Cue Biopharma	-$0.13	N/A	N/A	N/A	$2.00 million	N/A
8/11/2025	Q2 2025	ADVM Adverum Biotechnologies	-$2.24	N/A	N/A	N/A	N/A	N/A
7/14/2025	Q3 2025	LEXX Lexaria Bioscience	-$0.15	-$0.21	-$0.06	-$0.21	$0.17 million	$0.17 million
5/12/2025	Q1 2025	CUE Cue Biopharma	-$0.14	-$0.17	-$0.03	-$0.17	$0.90 million	$0.42 million
5/8/2025	Q1 2025	HOWL Werewolf Therapeutics	-$0.44	-$0.40	+$0.04	-$0.40	$0.30 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
CUE Cue Biopharma	N/A	1.03	1.03
HOWL Werewolf Therapeutics	0.46	8.09	8.09
LEXX Lexaria Bioscience	N/A	3.90	4.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
CUE Cue Biopharma	35.04%
HOWL Werewolf Therapeutics	64.84%
LEXX Lexaria Bioscience	13.06%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
CUE Cue Biopharma	10.78%
HOWL Werewolf Therapeutics	23.60%
LEXX Lexaria Bioscience	26.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
CUE Cue Biopharma	60	75.35 million	67.23 million	Optionable
HOWL Werewolf Therapeutics	40	44.87 million	34.28 million	Optionable
LEXX Lexaria Bioscience	7	19.56 million	14.40 million	Not Optionable

LEXX, CUE, HOWL, and ADVM Headlines

Recent News About These Companies

LEXX - Lexaria Bioscience Corp Dividends - Morningstar

July 12, 2025 | morningstar.comM

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

June 23, 2025 | thenewswire.comT

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

June 23, 2025 | accessnewswire.comA

Lexaria Bioscience announces completion of GLP-1-H25-5 study

June 12, 2025 | finance.yahoo.com

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

June 11, 2025 | thenewswire.comT

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

June 11, 2025 | accessnewswire.comA

Lexaria Bioscience Corp.: Lexaria Attending BIO International Convention

June 5, 2025 | finanznachrichten.de

Lexaria Attending BIO International Convention

June 5, 2025 | thenewswire.comT

Lexaria Attending BIO International Convention

June 5, 2025 | accessnewswire.comA

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

May 12, 2025 | accessnewswire.comA

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

May 12, 2025 | thenewswire.comT

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

April 28, 2025 | thenewswire.comT

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

April 28, 2025 | accessnewswire.comA

Lexaria Bioscience prices 2M shares at $1.00 in registered direct offering

April 26, 2025 | markets.businessinsider.com

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

April 25, 2025 | accessnewswire.comA

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

April 25, 2025 | thenewswire.comT

Lexaria provides GLP-1 update following industry developments

April 23, 2025 | markets.businessinsider.com

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

April 23, 2025 | finance.yahoo.com

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

April 23, 2025 | accessnewswire.comA

We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully

April 5, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX, CUE, HOWL, and ADVM Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.77 -0.07 (-2.46%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.76 0.00 (-0.18%)

As of 07/18/2025 04:41 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Cue Biopharma NASDAQ:CUE

$0.90 +0.06 (+7.14%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.91 +0.01 (+0.67%)

As of 07/18/2025 07:58 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Werewolf Therapeutics NASDAQ:HOWL

$1.41 +0.01 (+0.71%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.40 0.00 (-0.35%)

As of 07/18/2025 06:53 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Lexaria Bioscience NASDAQ:LEXX

$0.95 +0.08 (+8.68%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.93 -0.01 (-1.32%)

As of 07/18/2025 07:43 PM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time